Joshua Farr

Has grant

Associate Professor

University of Arizona
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Joshua Farr is an Associate Professor at the University of Arizona, located in the United States. His research primarily focuses on skeletal health, senescence, and diabetes, as evidenced by his recent articles investigating skeletal and senescence phenotypes in young mice with juvenile onset Type 1 diabetes, as well as bone metabolism and senolytic therapy. He contributes to the understanding of the relationship between aging and bone loss through various studies exploring the effects of microRNA and local senolysis.

Recent Grants

Grant: Close

Targeting Cellular Senescence and RAGE in Type 2 Diabetes

Open Date: 2021-05-01

Close Date: 2024-08-04

Grant: Close

Targeting cellular senescence with senolytics to improve skeletal health in older humans

Open Date: 2020-02-15

Close Date: 2023-01-31

Grant: Close

The Role of Cellular Senescence in Mediating Age-Related Bone Loss

Open Date: 2016-08-01

Close Date: 2021-07-31

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Estrogen regulates bone mass in women and men, but the underlying cellular mechanisms of estrogen action on bone remain unclear. Although both estrogen receptor (ER)α and ERβ are expressed in bone cells, ERα is the dominant receptor for skeletal estrogen action. Previous studies using either global or cell‐specific ERα deletion provided important insights, but each of these approaches had limitations. Specifically, either high circulating sex steroid levels in global ERα knockout mice or the effects of deletion of ERα during growth and development in constitutive cell‐specific knockout mice have made it difficult to clearly define the role of ERα in specific cell types in the adult skeleton. We recently generated and characterized mice with tamoxifen‐inducible ERα deletion in osteocytes driven by the 8‐kb Dmp1 promoter (ERαΔOcy mice), revealing detrimental effects of osteocyte‐specific ERα deletion on trabecular bone volume (−20.1%) and bone formation rate (−18.9%) in female, but not male, mice. Here, we developed and characterized analogous mice with inducible ERα deletion in osteoclasts using the Cathepsin K promoter (ERαΔOcl mice). In a study design identical to that with the previously described ERαΔOcy mice, adult female, but not male, ERαΔOcl mice showed a borderline (−10.2%, p = 0.084) reduction in trabecular bone volume, no change in osteoclast numbers, but a significant increase in serum CTx levels, consistent with increased osteoclast activity. These findings in ERαΔOcl mice differ from previous studies of constitutive osteoclast‐specific ERα deletion, which led to clear deficits in trabecular bone and increased osteoclast numbers. Collectively, these data indicate that in adult mice, estrogen action in the osteocyte is likely more important than via the osteoclast and that ERα deletion in osteoclasts from conception onward has more dramatic skeletal effects than inducible osteoclastic ERα deletion in adult mice. © 2023 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Sundeep Khosla

-

UNITED STATES
View details

David G. Monroe

-

UNITED STATES
View details

Yi Zhu

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Joao Passos

Professor

Mayo Clinic

UNITED STATES
View details

Xavier Nogues

Associate Professor

Universitat Pompeu Fabra

SPAIN
View details

Mark Kotowicz

Professor in Endocrinology & Diabetes

Deakin University

AUSTRALIA
View details

Natasha M. Appelman‐Dijkstra

-

NETHERLANDS
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.